More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

DCAT Value Chain Insights

The global biotechnology industry set records in several financial metrics in 2014 and reached an historical first, $1 trillion in market capitalization. So will the good times continue? DCAT Value Chain Insights looks into the performance of the...
DCAT Value Chain Insights

The recent decision by the US National Institutes of Health (NIH) to suspend sterile manufacturing in its pharmaceutical development operations, based on a recent FDA inspection, underscores the challenges in achieving sterility assurance. A look...
DCAT Value Chain Insights

Patheon's announcement this week that it plans to file for an initial public offering (IPO) is the latest move by the company, which has been actively building its capabilities through targeted acquisitions. So what is the impact on the pharma...
DCAT Value Chain Insights

The annual meeting of the American Society of Clinical Oncology (ASCO) is an important event for pharmaceutical companies to share results of their most promising oncology drugs. With this year's meeting just completed, what were the highlights...
DCAT Value Chain Insights

Pharmaceutical companies and suppliers face critical issues as they seek to optimize their manufacturing supply chains, with strategies for effective risk management, supplier relationship management, and adoption of digital technologies topping...
DCAT Value Chain Insights

Risk management is on the agenda of CEOs across all industries, but what do they perceive as threats and what measures are they taking to mitigate these risks? DCAT Value Chain Insights (VCI) share perspectives from within and outside the pharma...
DCAT Value Chain Insights

Venture capital funding is an important measure of the health of emerging biopharmaceutical companies. A recent PwC study of venture capital funding for the first quarter shows some weakness as the amount of dollars invested declined, but the...
DCAT Value Chain Insights

At a meeting last week with industry analysts, senior leaders from the Janssen Pharmaceutical Companies of Johnson & Johnson announced plans to file for regulatory approval of more than 10 new products between 2015 and 2019, each with the...